ArticleInfection and immunity2002
Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation.
Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 111 citations in OpenAlex.
- Trial
- Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection.Oncoimmunology · 2023Article
- Engineering living therapeutics with synthetic biology.Nature reviews. Drug discovery · 2021Review
- Pathogenicity and virulence ofVirulence · 2021Article
- Clinical Experience and Recent Advances in the Development ofFrontiers in immunology · 2021Review
- Enhancing mucosal immunity by transient microbiota depletion.Nature communications · 2020Article
- The Beneficial Effect of Eco-Friendly Green Nanoparticles UsingAnimals : an open access journal from MDPI · 2020Article
- Checkpoint blockade inhibitors enhances the effectiveness of aOncotarget · 2020Article
- Heterologous Boosting WithFrontiers in immunology · 2020Article
- A Potent and Effective SuicidalInfection and immunity · 2019Article
- Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.Journal for immunotherapy of cancer · 2019Article
- Innate and Adaptive Immune Responses duringMicrobiology spectrum · 2019Article
- Engineering bacteria for diagnostic and therapeutic applications.Nature reviews. Microbiology · 2018Review
- Progesterone impairs antigen-non-specific immune protection by CD8 T memory cells via interferon-γ gene hypermethylation.PLoS pathogens · 2017Article
- GNP-GAPDHOncotarget · 2017Article
- YopE specific CD8+ T cells provide protection against systemic and mucosal Yersinia pseudotuberculosis infection.PloS one · 2017Article
- A Promising Listeria-Vectored Vaccine Induces Th1-Type Immune Responses and Confers Protection Against Tuberculosis.Frontiers in cellular and infection microbiology · 2017Article
- CD8(+) T cells specific to a single Yersinia pseudotuberculosis epitope restrict bacterial replication in the liver but fail to provide sterilizing immunity.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2016Article
- Identification and characterisation of T-cell epitopes for incorporation into dendritic cell-delivered Listeria vaccines.Journal of immunological methods · 2015Article
- An Excess of the Proinflammatory Cytokines IFN-γ and IL-12 Impairs the Development of the Memory CD8+ T Cell Response to Chlamydia trachomatis.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Listeria monocytogenes is an intracellular bacterial pathogen which causes bacteremia and has a tropism for the central nervous system and a propensity to cause maternofetal infection. L. monocytogenes has been shown to be an effective prophylactic and a therapeutic vaccine vector for viral and tumor antigens in animal models. L. monocytogenes mutants lacking the ActA protein, which is essential for intracellular movement, are attenuated but retain immunogenicity in mice. Given the pathogenic potential of L. monocytogenes, we created an attenuated mutant strain bearing double deletions in the actA and plcB virulence genes for an initial clinical safety study of a prototype L. monocytogenes vector in adults. Twenty healthy volunteers received single escalating oral doses (10(6) to 10(9) CFU, 4 volunteers per dose cohort) of this attenuated L. monocytogenes, designated LH1169. Volunteers were monitored in the hospital for 14 days with frequent clinical checks and daily blood and stool cultures, and they were monitored for six additional weeks as outpatients. There were no positive blood cultures and no fevers attributable to the investigational inoculation. Most volunteers shed vaccine bacteria for 4 days or less, without diarrhea. One volunteer had a late positive stool culture during outpatient follow-up. Three volunteers had abnormal liver function test results temporally associated with inoculation; one could be reasonably attributed to another cause. In the highest-dose cohort, humoral, mucosal, and cellular immune responses to the investigational organism were detected in individual volunteers. Attenuated L. monocytogenes can be studied in adult volunteers without serious long-term health sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.